
ACET Stock Forecast & Price Target
ACET Analyst Ratings
Bulls say
Adicet Bio is currently developing a promising pipeline of allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, the most advanced of which is their main product candidate, prulacabtagene leucel (prula-cel). The preliminary Phase 1 data released last year showed strong efficacy and safety in both lupus nephritis (LN) and systemic lupus erythematosus (SLE) patients, with 100% of LN patients achieving a renal response and significant reductions in SLE symptoms. With promising data, a less toxic profile, and potential for multiple indications in the future, Adicet Bio's stock has the potential to see significant upside.
Bears say
Adicet Bio is facing potential delays and regulatory challenges with its product candidates, as evidenced by the pushed back release date of topline results for prula-cel and the need for further interactions with the FDA for its LN pivotal study. While the company has a strong cash position, its ongoing need for financing puts it at risk for dilution and drag on earnings. This, coupled with potential competition in the market, leads to a negative outlook for Adicet Bio's stock.
This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ACET Analyst Forecast & Price Prediction
Start investing in ACET
Order type
Buy in
Order amount
Est. shares
0 shares